跳转至内容
Merck
CN
  • Where attention falls: Increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function.

Where attention falls: Increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function.

Experimental neurology (2014-05-09)
Martin Sarter, Roger L Albin, Aaron Kucinski, Cindy Lustig
摘要

Falls are a major source of hospitalization, long-term institutionalization, and death in older adults and patients with Parkinson's disease (PD). Limited attentional resources are a major risk factor for falls. In this review, we specify cognitive-behavioral mechanisms that produce falls and map these mechanisms onto a model of multi-system degeneration. Results from PET studies in PD fallers and findings from a recently developed animal model support the hypothesis that falls result from interactions between loss of basal forebrain cholinergic projections to the cortex and striatal dopamine loss. Striatal dopamine loss produces inefficient, low-vigor gait, posture control, and movement. Cortical cholinergic deafferentation impairs a wide range of attentional processes, including monitoring of gait, posture and complex movements. Cholinergic cell loss reveals the full impact of striatal dopamine loss on motor performance, reflecting loss of compensatory attentional supervision of movement. Dysregulation of dorsomedial striatal circuitry is an essential, albeit not exclusive, mediator of falls in this dual-system model. Because cholinergic neuromodulatory activity influences cortical circuitry primarily via stimulation of α4β2* nicotinic acetylcholine receptors, and because agonists at these receptors are known to benefit attentional processes in animals and humans, treating PD fallers with such agonists, as an adjunct to dopaminergic treatment, is predicted to reduce falls. Falls are an informative behavioral endpoint to study attentional-motor integration by striatal circuitry.

材料
Product Number
品牌
产品描述

Sigma-Aldrich
盐酸多巴胺 盐酸盐
Sigma-Aldrich
氯化乙酰胆碱, ≥99% (TLC)
Sigma-Aldrich
氯化乙酰胆碱, suitable for cell culture
Sigma-Aldrich
碘化乙酰胆碱, ≥97%
Supelco
盐酸多巴胺 盐酸盐, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
氯化乙酰胆碱, pkg of 150 mg (per vial)
Supelco
多巴胺盐酸盐标准液 CRM 盐酸盐 溶液, 1.0 mg/mL in methanol with 5% 1 M HCl (as free base), ampule of 1 mL, certified reference material, Cerilliant®
USP
氯化乙酰胆碱, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
溴化乙酰胆碱(拟胆碱药), ≥99%
盐酸多巴胺 盐酸盐, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
氯化乙酰胆碱, ≥99% (TLC), free-flowing, Redi-Dri
氯化乙酰胆碱, European Pharmacopoeia (EP) Reference Standard